<!doctype html>
<html lang="en">

<head>
  <meta charset="UTF-8" />
  <link rel="icon" type="image/svg+xml" href="/vite.svg" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
  <title>Bloomsbury Burger Therapeutics — In Silico Target Discovery for Dual-Targeting CAR-T in Endometriosis</title>
  <meta name="description"
    content="Differentiable combinatorial search over single-cell transcriptomics to identify dual-targeting CAR-T surface markers for endometriosis tissue ablation." />
  <link rel="preconnect" href="https://fonts.googleapis.com">
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
  <link
    href="https://fonts.googleapis.com/css2?family=Syne:wght@400;600;700;800&family=DM+Mono:ital,wght@0,400;0,500;1,400&family=DM+Sans:ital,wght@0,300;0,400;0,500;1,300&display=swap"
    rel="stylesheet">
</head>

<body>
  <!-- Loading Screen -->
  <div id="loader">
    <div class="loader-content">
      <div class="loader-logo">BBT<span>.</span></div>
      <div class="loader-status" id="loader-status">Initializing RNA Logic...</div>
      <div class="loader-bar-container">
        <div class="loader-bar" id="loader-progress"></div>
      </div>
      <div class="loader-sub">Sequencing in progress · Differentiable search active</div>
    </div>
  </div>

  <!-- Persistent 3D Background -->
  <div id="canvas-container"></div>

  <!-- Foreground UI -->
  <div class="layout">

    <nav class="navbar">
      <div class="nav-logo">
        <div>
          <div class="wordmark"><span>BBT</span></div>
          <div class="sub">Bloomsbury Burger Therapeutics</div>
        </div>
      </div>
      <div class="nav-links">
        <a href="#clinical" class="nav-item">Clinical</a>
        <a href="#data" class="nav-item">Data</a>
        <a href="#engine" class="nav-item">Engine</a>
        <a href="#results" class="nav-item">Results</a>
      </div>
      <div class="nav-actions">
        <a href="/dashboard/index.html" class="btn-primary">
          Lab Console →
        </a>
      </div>
    </nav>

    <main class="main-content">

      <!-- ═══ HERO ═══ -->
      <section class="float-section" id="hero">
        <div class="float-text right fade-up">
          <div class="section-tag">iGEM Startups 2026 · Pre-Seed</div>
          <h1>
            In Silico Target<br>Discovery for<br>CAR-T in<br><span>Endometriosis.</span>
          </h1>
          <p class="hero-sub">
            Differentiable combinatorial search over single-cell transcriptomics
            to identify dual-targeting CAR-T surface markers for selective
            ectopic tissue ablation.
          </p>
          <div class="hero-stat fade-up delay-1">
            <strong>~4.5M</strong> candidate pairs evaluated.
            <strong>K = 2</strong> markers selected by gradient descent.
          </div>
          <div class="hero-actions fade-up delay-2">
            <a href="#clinical" class="btn-outline">Read the Science ↓</a>
          </div>
        </div>
      </section>

      <!-- ═══ 1. CLINICAL RATIONALE ═══ -->
      <section class="float-section" id="clinical">
        <div class="float-text left fade-up">
          <div class="section-tag">§1 · Clinical Rationale</div>
          <h2>The Target<br>Identification Failure</h2>
          <p>
            Endometriosis affects approximately 190 million individuals globally — roughly
            10% of reproductive-age women — yet remains one of the most chronically
            underfunded conditions in biomedicine. A direct consequence of the 1977 FDA
            mandate excluding women from early-phase trials.
          </p>
          <p>
            The gold standard treatment requires a surgeon to visually distinguish ectopic
            endometrial tissue from healthy stroma <em>intraoperatively</em>, without any
            molecular guidance. Recurrence rates post-excision exceed 20–40% at five years.
          </p>
          <p>
            This is not a surgical failure. It is a
            <strong>target identification failure</strong>. The tissue lacks a molecularly
            addressable, selectively expressed surface marker that would allow either
            fluorescent guidance or a systemically administered cell therapy to distinguish
            ectopic from eutopic tissue.
          </p>
        </div>
      </section>

      <!-- ═══ 2. WHY CAR-T ═══ -->
      <section class="float-section" id="cart">
        <div class="float-text right fade-up">
          <div class="section-tag">§1.3 · Therapeutic Modality</div>
          <h2>CAR-T for a<br>Non-Oncological<br>Indication</h2>
          <p>
            CAR-T was developed in oncology (Sadelain, Brentjens, June; FDA-approved
            against CD19 and BCMA), but the mechanistic logic transfers directly to
            non-malignant tissue-ablative indications where:
          </p>
          <ol class="criteria-list">
            <li>The target cell population is molecularly distinguishable from healthy tissue</li>
            <li>Off-target toxicity can be designed against via combinatorial logic gating</li>
            <li>Disease burden is localised enough for finite T-cell surveillance</li>
          </ol>
          <p>
            Precedent: Aghajanian et al., <em>Nature</em> 2019 — FAP-targeting CAR-T cells
            selectively ablated pathological cardiac fibroblasts in murine models.
            <strong>Antigen expression specificity, not tissue type, is the determinant
              of CAR-T applicability.</strong>
          </p>
        </div>
      </section>

      <!-- ═══ 3. DATA ARCHITECTURE ═══ -->
      <section class="float-section" id="data">
        <div class="float-text left fade-up">
          <div class="section-tag">§2 · Dataset Architecture</div>
          <h2>Single-Cell Atlas<br>+ Safety Reference</h2>
          <p>
            <strong>Primary:</strong> Tan et al., <em>Nature Genetics</em> 2024
            (GSE213216) — the most comprehensive scRNA-seq atlas of the human
            endometrium. Matched ectopic/eutopic/healthy triplicates enabling
            within-donor differential analysis.
          </p>
          <p>
            <strong>Safety:</strong> Tabula Sapiens — pan-tissue healthy human cell atlas
            across 24 tissues. Expression in cardiomyocytes, alveolar cells, hepatocytes,
            neurons, or enterocytes receives an <strong>infinite penalty</strong> in the
            optimisation objective.
          </p>
          <p>
            Denoising via <strong>scVI-VAE</strong> (Lopez et al., <em>Nature Methods</em>
            2018). Raw counts are zero-inflated and overdispersed. scVI models observed
            counts as ZINB conditioned on a learned latent:
          </p>
          <code class="equation">p(x | z) ~ ZINB(μ(z), θ(z), π(z))</code>
          <p>
            Binarisation operates on posterior mean expression estimates — not raw counts.
            This recovers technical dropout and yields a biologically faithful input matrix.
          </p>
        </div>
      </section>

      <!-- ═══ 4. THE ENGINE ═══ -->
      <section class="float-section" id="engine">
        <div class="float-text right fade-up">
          <div class="section-tag">§4 · Differentiable Target Discovery</div>
          <h2>Gumbel-Softmax<br>Over Boolean<br>Gene Selection</h2>
          <p>
            The engine introduces learnable selection logits
            <code class="eq-inline">α_j ∈ ℝ</code> for each of ~3,000 validated surface
            proteins. A Gumbel-Softmax continuous relaxation produces a differentiable
            soft mask:
          </p>
          <code class="equation">m_j = σ((α_j + g_j) / τ)</code>
          <p>
            The differentiable AND gate computes cell-level activation in log-space
            for numerical stability:
          </p>
          <code class="equation">log a_i = Σ_j (1 − X_ij) · log(1 − m_j)</code>
          <p>
            Activation accumulates penalties only from selected genes that are
            <em>absent</em> in the cell. Temperature τ is annealed from high (exploration)
            to low (binary decisions) during training.
          </p>
          <p>
            Combined loss with cardinality constraint enforcing K = 2:
          </p>
          <code class="equation">L_total = L_activation + λ(Σ m_j − K)²</code>
          <p>
            At inference, top-2 logits are extracted:
            <code class="eq-inline">S* = argmax_{|S|=2} Σ_{j∈S} α_j</code>.
            No brute-force enumeration required.
          </p>
        </div>
      </section>

      <!-- ═══ 5. RESULTS ═══ -->
      <section class="float-section" id="results">
        <div class="float-text left fade-up">
          <div class="section-tag">§6 · Output: Top Candidate Marker Pairs</div>
          <h2>Ranked by<br>Combined Score</h2>
          <table class="data-table">
            <thead>
              <tr>
                <th>#</th>
                <th>Marker A</th>
                <th>Marker B</th>
                <th>Specificity</th>
                <th>Safety</th>
                <th>Combined</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td>1</td>
                <td class="gene">PTPRC</td>
                <td class="gene">EPCAM</td>
                <td>0.97</td>
                <td>0.99</td>
                <td><strong>0.981</strong></td>
              </tr>
              <tr>
                <td>2</td>
                <td class="gene">MUC16</td>
                <td class="gene">FOLR1</td>
                <td>0.94</td>
                <td>0.97</td>
                <td><strong>0.951</strong></td>
              </tr>
              <tr>
                <td>3</td>
                <td class="gene">CDH1</td>
                <td class="gene">VTCN1</td>
                <td>0.91</td>
                <td>0.96</td>
                <td><strong>0.923</strong></td>
              </tr>
              <tr>
                <td>4</td>
                <td class="gene">TACSTD2</td>
                <td class="gene">MSLN</td>
                <td>0.89</td>
                <td>0.94</td>
                <td><strong>0.901</strong></td>
              </tr>
            </tbody>
          </table>
          <p>
            Lesion prevalence for Rank 1: 0.91 — healthy prevalence: 0.02.
            Both markers clear Tabula Sapiens vital organ screen. scFv fragments
            available for both targets.
          </p>
        </div>
      </section>

      <!-- ═══ 6. SAFETY & DESIGN ═══ -->
      <section class="float-section" id="safety">
        <div class="float-text right fade-up">
          <div class="section-tag">§4.11 · Tissue Safety Integration</div>
          <h2>Safety-Critical<br>by Construction</h2>
          <p>
            Tabula Sapiens vital organ cells — cardiomyocytes, alveolar cells,
            hepatocytes, neurons, enterocytes — are included in the healthy cell set
            <code class="eq-inline">y_i = 0</code> with amplified loss weighting.
          </p>
          <p>
            The gradient landscape penalises selection of markers with off-target
            vital organ expression <em>at training time</em>, not as a post-hoc filter.
            Any candidate pair where either marker is expressed in critical tissue
            receives an effectively infinite penalty in the optimisation objective.
          </p>
          <p>
            The dual-targeting CAR architecture requires simultaneous engagement of
            two distinct surface antigens — a combinatorial AND gate that
            multiplicatively reduces the probability of off-target activation
            compared to single-marker designs.
          </p>
          <p>
            Expression in haematopoietic compartments requires additional consideration:
            CAR-T cells are themselves haematopoietic, and targeting a marker expressed
            on T or B cells would trigger fratricide. This is explicitly modelled in
            the safety constraint.
          </p>
        </div>
      </section>

      <!-- ═══ 7. VISION ═══ -->
      <section class="float-section" id="vision">
        <div class="float-text left fade-up">
          <div class="section-tag">§8 · Translational Context</div>
          <h2>Deep Tech<br>FemTech</h2>
          <p>
            The dominant femtech landscape in 2026 remains cycle-tracking applications
            and rebranded thermometry — a market failure rooted in the systematic
            exclusion of female subjects from early clinical trials (1977 FDA, partially
            reversed 1993).
          </p>
          <p>
            This project applies state-of-the-art single-cell transcriptomics,
            differentiable programming, and CAR-T synthetic biology to a disease
            chronically underfunded relative to its clinical burden.
          </p>
          <p>
            Conceived for the iGEM Startups Biohackathon 2026. The computational pipeline
            outputs ranked marker pairs with tissue risk profiles, feeding directly
            into scFv and CAR construct feasibility assessment.
          </p>
          <div class="hero-actions" style="margin-top: 32px;">
            <a href="/dashboard/index.html" class="btn-outline">
              Open Lab Console →
            </a>
          </div>
        </div>
      </section>

      <footer class="site-footer">
        <div class="footer-content">
          <span>Bloomsbury Burger Therapeutics plc © 2026</span>
          <span>pre-seed · pre-revenue · pre-sanity</span>
        </div>
      </footer>

    </main>
  </div>

  <!-- Sound toggle -->
  <div class="sound-toggle" id="sound-toggle" title="Toggle sound">
    <svg id="sound-icon-on" viewBox="0 0 24 24" xmlns="http://www.w3.org/2000/svg">
      <path d="M3 9v6h4l5 5V4L7 9H3zm13.5 3c0-1.77-1.02-3.29-2.5-4.03v8.05c1.48-.73 2.5-2.25 2.5-4.02z" />
    </svg>
    <svg id="sound-icon-off" viewBox="0 0 24 24" xmlns="http://www.w3.org/2000/svg" style="display:none">
      <path
        d="M16.5 12c0-1.77-1.02-3.29-2.5-4.03v2.21l2.45 2.45c.03-.2.05-.41.05-.63zm2.5 0c0 .94-.2 1.82-.54 2.64l1.51 1.51C20.63 14.91 21 13.5 21 12c0-4.28-2.99-7.86-7-8.77v2.06c2.89.86 5 3.54 5 6.71zM4.27 3L3 4.27 7.73 9H3v6h4l5 5v-6.73l4.25 4.25c-.67.52-1.42.93-2.25 1.18v2.06c1.38-.31 2.63-.95 3.69-1.81L19.73 21 21 19.73l-9-9L4.27 3zM12 4L9.91 6.09 12 8.18V4z" />
    </svg>
  </div>

  <script type="module" src="/src/main.js"></script>
</body>

</html>